Tg Therapeutics (TGTX) Cash from Operations Growth (3y) (2014 - 2026)

Tg Therapeutics (TGTX) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Tg Therapeutics 8.10 Bn 8.03 Bn 171.41 Mn 33.15%

Historic Data

Download Data
DateValue
Mar 31, 2026 33.15%
Dec 31, 2025 41.34%
Sep 30, 2025 12.44%
Jun 30, 2025 29.09%
Mar 31, 2025 25.23%
Dec 31, 2024 33.43%
Sep 30, 2024 43.37%
Jun 30, 2024 27.90%
Mar 31, 2024 53.45%
Dec 31, 2023 36.68%
Sep 30, 2023 51.55%
Jun 30, 2023 1.41%
Mar 31, 2023 1.20%
Dec 31, 2022 7.74%
Sep 30, 2022 -1.28%
Jun 30, 2022 -11.05%
Mar 31, 2022 -27.23%
Dec 31, 2021 -37.15%
Sep 30, 2021 -26.74%
Jun 30, 2021 -20.74%